

Our Team of Expert Consultants

Available to help support you in managing your patient's CLOZARIL® treatment

 Dr. Jaroslav Prchal, Hematologist, Bilingual	 Dr. Sean Flynn, Psychiatrist	 Dr. Richard Choi, Cardiologist
 Dr. Jean-François de la Sablonnière, Psychiatrist, Bilingual	 Dr. Jean Grégoire, Cardiologist, Bilingual	 Marilyn Rabin, Nutritionist, Bilingual

 Full-time bilingual Patient Support Program coordinators and nurse educators are assigned in tandem to a specific institution. Together, they help manage the use of CLOZARIL® for your patient and assist you with hematological monitoring and management, discharge coordination, vacation planning, and more.

 CSAN® services are available **24/7/365**, including holidays. Contact us for any program-related assistance you may require, such as using the CSAN® Patient Care Portal.

^PCLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment-resistant schizophrenia. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms.¹

Contact CSAN® at 1-800-267-2726 or CSAN@HLStherapeutics.com

For patients treated with CLOZARIL® The CSAN® program aims to go beyond to help in patient management

CSAN® offers a range of services designed to help care for patients throughout their CLOZARIL® treatment.

 Support 24/7/365	 Nurse Educators	 Expert Consultants	 BEN* Protocol	 Financial Assistance
 Travel Assistance Service	 Lablink+	 CSAN® Pronto®	 CSAN® Patient Care Portal	*BEN: benign ethnic neutropenia

CSAN® aims to streamline the hematological monitoring of patients on CLOZARIL®

CLOZARIL® is available only through the CSAN® distribution system that ensures weekly, every-two-week or every-four-week hematological testing prior to the dispensing of the next period's supply of CLOZARIL®.¹

- To help simplify routine hematological monitoring required for patients treated with CLOZARIL®, CSAN® Pronto® offers onsite testing and can generate white blood cell counts/neutrophil percentage from a drop of capillary-drawn blood.



 **The switching of a patient from one brand of clozapine to another must not be done by a pharmacist unless they obtain a new, registry-specific patient registration form filled out by the prescribing physician. The physician must inform their patient about the potential sharing of information between clozapine registries and document if there is consent.¹**

Scan the QR code to access CLOZARIL.ca



Please consult the CLOZARIL® Product Monograph at http://www.hlstherapeutics.com/wp-content/uploads/monograph_pdf/HLS-Clozaril-PM-E.pdf for important information on contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-267-2726.

NIHB coverage assistance is available through the CSAN® Patient Support Program. CLOZARIL® is covered by the Non-Insured Health Benefits (NIHB) as an open benefit for all CLOZARIL® tablet strengths.² For more information on financial support, CLOZARIL® and CSAN® services, contact your sales representative or nurse educator.

References: 1. CLOZARIL® Product Monograph. HLS Therapeutics Inc. July 10, 2025. 2. NIHB Express Scripts Online Formulary Listing. Accessed December 2025 at: <https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407>.